Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin

We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP. We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2017-09, Vol.37 (9), p.5235-5239
Main Authors: Maeda, Akimitsu, Ando, Hitoshi, Ura, Takashi, Muro, Kei, Aoki, Masahiro, Saito, Ken, Kondo, Eisaku, Takahashi, Shinji, Ito, Yuko, Mizuno, Yasunari, Fujimura, Akio
Format: Article
Language:English
Subjects:
Acute Kidney Injury - blood
Acute Kidney Injury - chemically induced
Analysis of Variance
Biomarkers - blood
Biomarkers - urine
Cisplatin - administration & dosage
Cisplatin - adverse effects
Creatinine - blood
Female
Humans
Male
Middle Aged
Neoplasms - blood
Neoplasms - drug therapy
Time Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP. We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline. NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline. Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.11947